Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with Article R-163-21 of the French Social Security Code. Renewal of inclusion on the list of medicines refundable by National Health Insurance.
-
Clinical Benefit
Substantial
The actual benefit of SOLIAN in the treatment of schizophrenia remains substantial.
Clinical Added Value
moderate
Like all other antipsychotics (including first generation antipsychotics), SOLIAN provides a moderate improvement in actual benefit (IAB III) in the treatment of schizophrenia.
Listen
